Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults

Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults

Vaccination with the 13-valent pneumococcal conjugate vaccine (PCV13) followed ≥ 1 year by the 23-valent pneumococcal polysaccharide vaccine (PPSV23) is recommended for immunocompetent adults ≥ 65 years of age in the United States. This study assessed antipneumococcal opsonophagocytic activity (OPA)...

Full description

Bibliographic Details
Main Authors: Beate Schmoele-Thoma, Martin van Cleeff, Richard N. Greenberg, Alejandra Gurtman, Thomas R. Jones, Vani Sundaraiyer, William C. Gruber, Daniel A. Scott
Format: Article
Language:English
Published: Taylor & Francis Group 2019-03-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
antibody persistence
13-valent pneumococcal conjugate vaccine
opsonophagocytic activity
adults
clinical studies
Online Access:http://dx.doi.org/10.1080/21645515.2018.1538618

Internet

http://dx.doi.org/10.1080/21645515.2018.1538618

Similar Items